CA2460095A1 - Methods for targeted expression of therapeutic nucleic acid - Google Patents

Methods for targeted expression of therapeutic nucleic acid Download PDF

Info

Publication number
CA2460095A1
CA2460095A1 CA002460095A CA2460095A CA2460095A1 CA 2460095 A1 CA2460095 A1 CA 2460095A1 CA 002460095 A CA002460095 A CA 002460095A CA 2460095 A CA2460095 A CA 2460095A CA 2460095 A1 CA2460095 A1 CA 2460095A1
Authority
CA
Canada
Prior art keywords
promoter
seq
cell
tcf
catenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460095A
Other languages
English (en)
French (fr)
Inventor
Richard R. Drake
Saurabh K. Gupta
Kelly E. Mercer
Robyn Mcmasters
Mary Pat Moyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
INCELL Corp LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460095A1 publication Critical patent/CA2460095A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002460095A 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid Abandoned CA2460095A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29783101P 2001-06-13 2001-06-13
US60/297,831 2001-06-13
US36113702P 2002-03-01 2002-03-01
US60/361,137 2002-03-01
PCT/US2002/018650 WO2002101076A2 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Publications (1)

Publication Number Publication Date
CA2460095A1 true CA2460095A1 (en) 2003-12-19

Family

ID=26970335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460095A Abandoned CA2460095A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Country Status (5)

Country Link
EP (1) EP1461427A4 (ja)
JP (1) JP2005504520A (ja)
AU (1) AU2002345658A1 (ja)
CA (1) CA2460095A1 (ja)
WO (1) WO2002101076A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1943265B1 (en) * 2005-10-01 2012-09-12 Charles Stout Regulatable fusion promoters
CN105518149A (zh) * 2013-03-24 2016-04-20 奥依信生物技术公司 靶细胞内治疗性蛋白的靶向产生的系统和方法
CN109715797A (zh) * 2016-05-25 2019-05-03 斯坦福大学托管董事会 活性依赖性表达构建体以及其使用方法
US11525146B2 (en) 2017-01-09 2022-12-13 Oisin Biotechnologies, Inc. Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof
WO2019204666A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
CN110964747A (zh) * 2019-11-26 2020-04-07 深圳市人民医院 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4
MXPA02008637A (es) * 2000-03-02 2004-09-06 Ml Lab Plc Elemento de respuesta a factor de celulas t.

Also Published As

Publication number Publication date
JP2005504520A (ja) 2005-02-17
WO2002101076A3 (en) 2004-07-22
EP1461427A4 (en) 2006-02-15
EP1461427A2 (en) 2004-09-29
WO2002101076A2 (en) 2002-12-19
AU2002345658A1 (en) 2002-12-23

Similar Documents

Publication Publication Date Title
Gouble et al. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice
Nam et al. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells
Tomlinson et al. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Sureban et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe
Pinto et al. Regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of small and large intestines
KR20010099682A (ko) 단일가닥 ｄｎａ의 효소 합성
Flajollet et al. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin
JP2005522225A (ja) 亢進された遺伝子発現系
Yu et al. Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR
Ohradanova et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2
Takeuchi et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice
JP4845327B2 (ja) 腫瘍特異的プロモーター
CA2460095A1 (en) Methods for targeted expression of therapeutic nucleic acid
Morice et al. Involvement of the TGF-β signaling pathway in the development of YAP-driven osteosarcoma lung metastasis
Wu et al. Study on the targeted therapy of oral squamous cell carcinoma with a plasmid expressing PE38KDEL toxin under control of the SERPINB3 promoter
Presta et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene
Armstrong et al. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma
Poulsen et al. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells
US8436160B2 (en) Isolated DNA fragment of the SPARC human promoter and its use for driving the expression of an heterologous gene in tumor cells
Wang et al. Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo
JP2002537807A (ja) 前立腺特異的膜抗原遺伝子のイントロン３を含む調節構築物
KR20230041475A (ko) 뇌 종양 동물 모델의 제조 방법, 이 방법에 의해 제조된 뇌 종양 동물 모델, 및 이 모델을 이용한 뇌 종양 치료제의 스크리닝 방법
Rusinek et al. Mouse models of papillary thyroid carcinoma—Short review
Inase et al. Use of gastrin‐releasing peptide promoter for specific expression of thymidine kinase gene in small‐cell lung carcinoma cells
CN114846156A (zh) Hla-h、hla-j、hla-l、hla-v和hla-y作为治疗和诊断靶

Legal Events

Date Code Title Description
FZDE Dead